New Drug-Coated membrane targets sarcoma after surgery

NCT ID NCT04619056

Completed Disease control Sponsor: CEBIOTEX Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a special membrane loaded with the drug SN-38 in 21 people with recurrent or advanced retroperitoneal sarcoma. The membrane was placed in the surgical area after tumor removal to see if it is safe and tolerable. The goal is to find the right dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CEB-01 membrane loaded with SN-38 (a chemotherapy drug)
What this could lead to: If successful, this could lead to a new treatment option that helps prevent sarcoma from coming back after surgery.
What could go wrong: This is a very early Phase 1 trial with only 21 people, so safety and dosing are still being figured out. It may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Recurrence retroperitoneal sarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED SOFT TISSUE SARCOMA RECURRENT SOFT TISSUE SARCOMA

Contacts and locations

Locations

Fundación Jiménez Díaz

Madrid, Madrid, 28040, Spain
Hospital General Universitario Gregorio Marañón

Madrid, Madrid, 28007, Spain
Hospital Universitario Vall d'Hebron

Barcelona, Barcelona, 08035, Spain
Hospital Universitario y Politécnico La Fe

Valencia, Valencia, 46026, Spain
Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, 08041, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.